DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease
Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, double-dummy, and controlled study of
DLBS1033 for the improvement of ankle-brachial index in diabetic patients with peripheral
arterial disease (PAD). It is hypothesized that the addition of DLBS1033 on top of aspirin
treatment will augment significantly the resting ABI in diabetes patient with PAD in
comparison with that of aspirin alone.